肝硬変治療薬のグローバル市場2024-2028:経口剤、注射剤

【英語タイトル】Global Liver Cirrhosis Therapeutics Market 2024-2028

Technavioが出版した調査資料(IRTNTR76818-24)・商品コード:IRTNTR76818-24
・発行会社(調査会社):Technavio
・発行日:2023年11月17日
・ページ数:約120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

肝硬変治療薬の世界市場2024〜2028年肝硬変治療薬市場は2023年から2028年にかけて19億4000万米ドル成長し、予測期間中のCAGRは5.58%で加速すると予測されます。当レポートでは、肝硬変治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題に加え、約25のベンダーを網羅したベンダー分析も提供しています。
当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。肝癌の罹患率の増加、医学研究の進歩、製薬企業と医療提供者の協力関係の増加などが市場を牽引しています。

Technavio社の肝硬変治療薬市場は以下のように分類されます:
タイプ別
- 経口剤
- 注射剤

エンドユーザー別
- 病院
- クリニック
- 研究・学術機関

地域別
- 北米
- ヨーロッパ
- アジア
- その他の地域(ROW)

本調査では、今後数年間における肝硬変治療薬市場の成長を促進する主な要因の一つとして、個別化医療への傾向を挙げています。また、非侵襲的な治療オプションやデジタルヘルス技術の統合が重視されるようになることも、同市場の大きな需要につながるでしょう。

肝硬変治療薬市場のレポートでは、以下の分野をカバーしています:
- 肝硬変治療薬市場の規模
- 肝硬変治療薬市場の予測
- 肝硬変治療薬市場の産業分析

本レポートでは、肝硬変治療薬市場の主要ベンダーであるAbbVie Inc., Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, CSL Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Gwo Xi Stem Cell Applied Technology, Johnson and Johnson, Kezar Life Sciences Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Protagonist Therapeutics Inc., and Tessera Therapeutics.などを分析しています。また、肝硬変治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。

当出版社は、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細な姿を提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1 エグゼクティブサマリー
2 市場概況
3 市場規模
4 過去の市場規模
5 ファイブフォース分析
6 世界の肝硬変治療薬市場規模:種類別分析
7 世界の肝硬変治療薬市場規模:エンドユーザー別分析
8 顧客状況
9 地域別状況
10 推進要因・課題・動向
11 企業状況
12 企業分析
13 付録

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global – Market size and forecast 2023-2028 ($ billion)
o Exhibit 15: Data Table on Global – Market size and forecast 2023-2028 ($ billion)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global liver cirrhosis therapeutics market 2018 – 2022
o Exhibit 18: Historic Market Size – Data Table on global liver cirrhosis therapeutics market 2018 – 2022 ($ billion)
o 4.2 Type Segment Analysis 2018 – 2022
o Exhibit 19: Historic Market Size – Type Segment 2018 – 2022 ($ billion)
o 4.3 End-user Segment Analysis 2018 – 2022
o Exhibit 20: Historic Market Size – End-user Segment 2018 – 2022 ($ billion)
o 4.4 Geography Segment Analysis 2018 – 2022
o Exhibit 21: Historic Market Size – Geography Segment 2018 – 2022 ($ billion)
o 4.5 Country Segment Analysis 2018 – 2022
o Exhibit 22: Historic Market Size – Country Segment 2018 – 2022 ($ billion)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2023 and 2028
• 6 Market Segmentation by Type
o 6.1 Market segments
o Exhibit 30: Chart on Type – Market share 2023-2028 (%)
o Exhibit 31: Data Table on Type – Market share 2023-2028 (%)
o 6.2 Comparison by Type
o Exhibit 32: Chart on Comparison by Type
o Exhibit 33: Data Table on Comparison by Type
o 6.3 Oral – Market size and forecast 2023-2028
o Exhibit 34: Chart on Oral – Market size and forecast 2023-2028 ($ billion)
o Exhibit 35: Data Table on Oral – Market size and forecast 2023-2028 ($ billion)
o Exhibit 36: Chart on Oral – Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Oral – Year-over-year growth 2023-2028 (%)
o 6.4 Injection – Market size and forecast 2023-2028
o Exhibit 38: Chart on Injection – Market size and forecast 2023-2028 ($ billion)
o Exhibit 39: Data Table on Injection – Market size and forecast 2023-2028 ($ billion)
o Exhibit 40: Chart on Injection – Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Injection – Year-over-year growth 2023-2028 (%)
o 6.5 Market opportunity by Type
o Exhibit 42: Market opportunity by Type ($ billion)
o Exhibit 43: Data Table on Market opportunity by Type ($ billion)
• 7 Market Segmentation by End-user
o 7.1 Market segments
o Exhibit 44: Chart on End-user – Market share 2023-2028 (%)
o Exhibit 45: Data Table on End-user – Market share 2023-2028 (%)
o 7.2 Comparison by End-user
o Exhibit 46: Chart on Comparison by End-user
o Exhibit 47: Data Table on Comparison by End-user
o 7.3 Hospitals – Market size and forecast 2023-2028
o Exhibit 48: Chart on Hospitals – Market size and forecast 2023-2028 ($ billion)
o Exhibit 49: Data Table on Hospitals – Market size and forecast 2023-2028 ($ billion)
o Exhibit 50: Chart on Hospitals – Year-over-year growth 2023-2028 (%)
o Exhibit 51: Data Table on Hospitals – Year-over-year growth 2023-2028 (%)
o 7.4 Clinics – Market size and forecast 2023-2028
o Exhibit 52: Chart on Clinics – Market size and forecast 2023-2028 ($ billion)
o Exhibit 53: Data Table on Clinics – Market size and forecast 2023-2028 ($ billion)
o Exhibit 54: Chart on Clinics – Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Clinics – Year-over-year growth 2023-2028 (%)
o 7.5 Research and academic institutes – Market size and forecast 2023-2028
o Exhibit 56: Chart on Research and academic institutes – Market size and forecast 2023-2028 ($ billion)
o Exhibit 57: Data Table on Research and academic institutes – Market size and forecast 2023-2028 ($ billion)
o Exhibit 58: Chart on Research and academic institutes – Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Research and academic institutes – Year-over-year growth 2023-2028 (%)
o 7.6 Market opportunity by End-user
o Exhibit 60: Market opportunity by End-user ($ billion)
o Exhibit 61: Data Table on Market opportunity by End-user ($ billion)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2023-2028
o Exhibit 67: Chart on North America – Market size and forecast 2023-2028 ($ billion)
o Exhibit 68: Data Table on North America – Market size and forecast 2023-2028 ($ billion)
o Exhibit 69: Chart on North America – Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on North America – Year-over-year growth 2023-2028 (%)
o 9.4 Europe – Market size and forecast 2023-2028
o Exhibit 71: Chart on Europe – Market size and forecast 2023-2028 ($ billion)
o Exhibit 72: Data Table on Europe – Market size and forecast 2023-2028 ($ billion)
o Exhibit 73: Chart on Europe – Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on Europe – Year-over-year growth 2023-2028 (%)
o 9.5 Asia – Market size and forecast 2023-2028
o Exhibit 75: Chart on Asia – Market size and forecast 2023-2028 ($ billion)
o Exhibit 76: Data Table on Asia – Market size and forecast 2023-2028 ($ billion)
o Exhibit 77: Chart on Asia – Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Asia – Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2023-2028
o Exhibit 79: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ billion)
o Exhibit 80: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ billion)
o Exhibit 81: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o 9.7 US – Market size and forecast 2023-2028
o Exhibit 83: Chart on US – Market size and forecast 2023-2028 ($ billion)
o Exhibit 84: Data Table on US – Market size and forecast 2023-2028 ($ billion)
o Exhibit 85: Chart on US – Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on US – Year-over-year growth 2023-2028 (%)
o 9.8 Germany – Market size and forecast 2023-2028
o Exhibit 87: Chart on Germany – Market size and forecast 2023-2028 ($ billion)
o Exhibit 88: Data Table on Germany – Market size and forecast 2023-2028 ($ billion)
o Exhibit 89: Chart on Germany – Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on Germany – Year-over-year growth 2023-2028 (%)
o 9.9 UK – Market size and forecast 2023-2028
o Exhibit 91: Chart on UK – Market size and forecast 2023-2028 ($ billion)
o Exhibit 92: Data Table on UK – Market size and forecast 2023-2028 ($ billion)
o Exhibit 93: Chart on UK – Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on UK – Year-over-year growth 2023-2028 (%)
o 9.10 Japan – Market size and forecast 2023-2028
o Exhibit 95: Chart on Japan – Market size and forecast 2023-2028 ($ billion)
o Exhibit 96: Data Table on Japan – Market size and forecast 2023-2028 ($ billion)
o Exhibit 97: Chart on Japan – Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on Japan – Year-over-year growth 2023-2028 (%)
o 9.11 China – Market size and forecast 2023-2028
o Exhibit 99: Chart on China – Market size and forecast 2023-2028 ($ billion)
o Exhibit 100: Data Table on China – Market size and forecast 2023-2028 ($ billion)
o Exhibit 101: Chart on China – Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on China – Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 103: Market opportunity By Geographical Landscape ($ billion)
o Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ billion)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 Alnylam Pharmaceuticals Inc.
o Exhibit 111: Alnylam Pharmaceuticals Inc. – Overview
o Exhibit 112: Alnylam Pharmaceuticals Inc. – Product / Service
o Exhibit 113: Alnylam Pharmaceuticals Inc. – Key news
o Exhibit 114: Alnylam Pharmaceuticals Inc. – Key offerings
o 12.4 Astellas Pharma Inc.
o Exhibit 115: Astellas Pharma Inc. – Overview
o Exhibit 116: Astellas Pharma Inc. – Product / Service
o Exhibit 117: Astellas Pharma Inc. – Key news
o Exhibit 118: Astellas Pharma Inc. – Key offerings
o 12.5 AstraZeneca Plc
o Exhibit 119: AstraZeneca Plc – Overview
o Exhibit 120: AstraZeneca Plc – Product / Service
o Exhibit 121: AstraZeneca Plc – Key news
o Exhibit 122: AstraZeneca Plc – Key offerings
o 12.6 CSL Ltd.
o Exhibit 123: CSL Ltd. – Overview
o Exhibit 124: CSL Ltd. – Business segments
o Exhibit 125: CSL Ltd. – Key offerings
o Exhibit 126: CSL Ltd. – Segment focus
o 12.7 F. Hoffmann La Roche Ltd.
o Exhibit 127: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 128: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 129: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 130: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 131: F. Hoffmann La Roche Ltd. – Segment focus
o 12.8 Gilead Sciences Inc.
o Exhibit 132: Gilead Sciences Inc. – Overview
o Exhibit 133: Gilead Sciences Inc. – Product / Service
o Exhibit 134: Gilead Sciences Inc. – Key news
o Exhibit 135: Gilead Sciences Inc. – Key offerings
o 12.9 GlaxoSmithKline Plc
o Exhibit 136: GlaxoSmithKline Plc – Overview
o Exhibit 137: GlaxoSmithKline Plc – Business segments
o Exhibit 138: GlaxoSmithKline Plc – Key news
o Exhibit 139: GlaxoSmithKline Plc – Key offerings
o Exhibit 140: GlaxoSmithKline Plc – Segment focus
o 12.10 Gwo Xi Stem Cell Applied Technology
o Exhibit 141: Gwo Xi Stem Cell Applied Technology – Overview
o Exhibit 142: Gwo Xi Stem Cell Applied Technology – Product / Service
o Exhibit 143: Gwo Xi Stem Cell Applied Technology – Key offerings
o 12.11 Johnson and Johnson
o Exhibit 144: Johnson and Johnson – Overview
o Exhibit 145: Johnson and Johnson – Business segments
o Exhibit 146: Johnson and Johnson – Key news
o Exhibit 147: Johnson and Johnson – Key offerings
o Exhibit 148: Johnson and Johnson – Segment focus
o 12.12 Kezar Life Sciences Inc.
o Exhibit 149: Kezar Life Sciences Inc. – Overview
o Exhibit 150: Kezar Life Sciences Inc. – Product / Service
o Exhibit 151: Kezar Life Sciences Inc. – Key news
o Exhibit 152: Kezar Life Sciences Inc. – Key offerings
o 12.13 Merck KGaA
o Exhibit 153: Merck KGaA – Overview
o Exhibit 154: Merck KGaA – Business segments
o Exhibit 155: Merck KGaA – Key news
o Exhibit 156: Merck KGaA – Key offerings
o Exhibit 157: Merck KGaA – Segment focus
o 12.14 Novartis AG
o Exhibit 158: Novartis AG – Overview
o Exhibit 159: Novartis AG – Business segments
o Exhibit 160: Novartis AG – Key offerings
o Exhibit 161: Novartis AG – Segment focus
o 12.15 Novo Nordisk AS
o Exhibit 162: Novo Nordisk AS – Overview
o Exhibit 163: Novo Nordisk AS – Business segments
o Exhibit 164: Novo Nordisk AS – Key offerings
o Exhibit 165: Novo Nordisk AS – Segment focus
o 12.16 Pfizer Inc.
o Exhibit 166: Pfizer Inc. – Overview
o Exhibit 167: Pfizer Inc. – Product / Service
o Exhibit 168: Pfizer Inc. – Key news
o Exhibit 169: Pfizer Inc. – Key offerings
o 12.17 Protagonist Therapeutics Inc.
o Exhibit 170: Protagonist Therapeutics Inc. – Overview
o Exhibit 171: Protagonist Therapeutics Inc. – Product / Service
o Exhibit 172: Protagonist Therapeutics Inc. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 173: Inclusions checklist
o Exhibit 174: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 175: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 176: Research methodology
o Exhibit 177: Validation techniques employed for market sizing
o Exhibit 178: Information sources
o 13.5 List of abbreviations
o Exhibit 179: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Type
Exhibits6: Executive Summary – Chart on Market Segmentation by End-user
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2023-2028 ($ billion)
Exhibits15: Data Table on Global – Market size and forecast 2023-2028 ($ billion)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size – Data Table on global liver cirrhosis therapeutics market 2018 – 2022 ($ billion)
Exhibits19: Historic Market Size – Type Segment 2018 – 2022 ($ billion)
Exhibits20: Historic Market Size – End-user Segment 2018 – 2022 ($ billion)
Exhibits21: Historic Market Size – Geography Segment 2018 – 2022 ($ billion)
Exhibits22: Historic Market Size – Country Segment 2018 – 2022 ($ billion)
Exhibits23: Five forces analysis – Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants – Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes – Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry – Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition – Five forces 2023 and 2028
Exhibits30: Chart on Type – Market share 2023-2028 (%)
Exhibits31: Data Table on Type – Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on Oral – Market size and forecast 2023-2028 ($ billion)
Exhibits35: Data Table on Oral – Market size and forecast 2023-2028 ($ billion)
Exhibits36: Chart on Oral – Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Oral – Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Injection – Market size and forecast 2023-2028 ($ billion)
Exhibits39: Data Table on Injection – Market size and forecast 2023-2028 ($ billion)
Exhibits40: Chart on Injection – Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Injection – Year-over-year growth 2023-2028 (%)
Exhibits42: Market opportunity by Type ($ billion)
Exhibits43: Data Table on Market opportunity by Type ($ billion)
Exhibits44: Chart on End-user – Market share 2023-2028 (%)
Exhibits45: Data Table on End-user – Market share 2023-2028 (%)
Exhibits46: Chart on Comparison by End-user
Exhibits47: Data Table on Comparison by End-user
Exhibits48: Chart on Hospitals – Market size and forecast 2023-2028 ($ billion)
Exhibits49: Data Table on Hospitals – Market size and forecast 2023-2028 ($ billion)
Exhibits50: Chart on Hospitals – Year-over-year growth 2023-2028 (%)
Exhibits51: Data Table on Hospitals – Year-over-year growth 2023-2028 (%)
Exhibits52: Chart on Clinics – Market size and forecast 2023-2028 ($ billion)
Exhibits53: Data Table on Clinics – Market size and forecast 2023-2028 ($ billion)
Exhibits54: Chart on Clinics – Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Clinics – Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Research and academic institutes – Market size and forecast 2023-2028 ($ billion)
Exhibits57: Data Table on Research and academic institutes – Market size and forecast 2023-2028 ($ billion)
Exhibits58: Chart on Research and academic institutes – Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Research and academic institutes – Year-over-year growth 2023-2028 (%)
Exhibits60: Market opportunity by End-user ($ billion)
Exhibits61: Data Table on Market opportunity by End-user ($ billion)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America – Market size and forecast 2023-2028 ($ billion)
Exhibits68: Data Table on North America – Market size and forecast 2023-2028 ($ billion)
Exhibits69: Chart on North America – Year-over-year growth 2023-2028 (%)
Exhibits70: Data Table on North America – Year-over-year growth 2023-2028 (%)
Exhibits71: Chart on Europe – Market size and forecast 2023-2028 ($ billion)
Exhibits72: Data Table on Europe – Market size and forecast 2023-2028 ($ billion)
Exhibits73: Chart on Europe – Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on Europe – Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Asia – Market size and forecast 2023-2028 ($ billion)
Exhibits76: Data Table on Asia – Market size and forecast 2023-2028 ($ billion)
Exhibits77: Chart on Asia – Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Asia – Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ billion)
Exhibits80: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ billion)
Exhibits81: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on US – Market size and forecast 2023-2028 ($ billion)
Exhibits84: Data Table on US – Market size and forecast 2023-2028 ($ billion)
Exhibits85: Chart on US – Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on US – Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on Germany – Market size and forecast 2023-2028 ($ billion)
Exhibits88: Data Table on Germany – Market size and forecast 2023-2028 ($ billion)
Exhibits89: Chart on Germany – Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on Germany – Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on UK – Market size and forecast 2023-2028 ($ billion)
Exhibits92: Data Table on UK – Market size and forecast 2023-2028 ($ billion)
Exhibits93: Chart on UK – Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on UK – Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on Japan – Market size and forecast 2023-2028 ($ billion)
Exhibits96: Data Table on Japan – Market size and forecast 2023-2028 ($ billion)
Exhibits97: Chart on Japan – Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on Japan – Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on China – Market size and forecast 2023-2028 ($ billion)
Exhibits100: Data Table on China – Market size and forecast 2023-2028 ($ billion)
Exhibits101: Chart on China – Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on China – Year-over-year growth 2023-2028 (%)
Exhibits103: Market opportunity By Geographical Landscape ($ billion)
Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ billion)
Exhibits105: Impact of drivers and challenges in 2023 and 2028
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: Alnylam Pharmaceuticals Inc. – Overview
Exhibits112: Alnylam Pharmaceuticals Inc. – Product / Service
Exhibits113: Alnylam Pharmaceuticals Inc. – Key news
Exhibits114: Alnylam Pharmaceuticals Inc. – Key offerings
Exhibits115: Astellas Pharma Inc. – Overview
Exhibits116: Astellas Pharma Inc. – Product / Service
Exhibits117: Astellas Pharma Inc. – Key news
Exhibits118: Astellas Pharma Inc. – Key offerings
Exhibits119: AstraZeneca Plc – Overview
Exhibits120: AstraZeneca Plc – Product / Service
Exhibits121: AstraZeneca Plc – Key news
Exhibits122: AstraZeneca Plc – Key offerings
Exhibits123: CSL Ltd. – Overview
Exhibits124: CSL Ltd. – Business segments
Exhibits125: CSL Ltd. – Key offerings
Exhibits126: CSL Ltd. – Segment focus
Exhibits127: F. Hoffmann La Roche Ltd. – Overview
Exhibits128: F. Hoffmann La Roche Ltd. – Business segments
Exhibits129: F. Hoffmann La Roche Ltd. – Key news
Exhibits130: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits131: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits132: Gilead Sciences Inc. – Overview
Exhibits133: Gilead Sciences Inc. – Product / Service
Exhibits134: Gilead Sciences Inc. – Key news
Exhibits135: Gilead Sciences Inc. – Key offerings
Exhibits136: GlaxoSmithKline Plc – Overview
Exhibits137: GlaxoSmithKline Plc – Business segments
Exhibits138: GlaxoSmithKline Plc – Key news
Exhibits139: GlaxoSmithKline Plc – Key offerings
Exhibits140: GlaxoSmithKline Plc – Segment focus
Exhibits141: Gwo Xi Stem Cell Applied Technology – Overview
Exhibits142: Gwo Xi Stem Cell Applied Technology – Product / Service
Exhibits143: Gwo Xi Stem Cell Applied Technology – Key offerings
Exhibits144: Johnson and Johnson – Overview
Exhibits145: Johnson and Johnson – Business segments
Exhibits146: Johnson and Johnson – Key news
Exhibits147: Johnson and Johnson – Key offerings
Exhibits148: Johnson and Johnson – Segment focus
Exhibits149: Kezar Life Sciences Inc. – Overview
Exhibits150: Kezar Life Sciences Inc. – Product / Service
Exhibits151: Kezar Life Sciences Inc. – Key news
Exhibits152: Kezar Life Sciences Inc. – Key offerings
Exhibits153: Merck KGaA – Overview
Exhibits154: Merck KGaA – Business segments
Exhibits155: Merck KGaA – Key news
Exhibits156: Merck KGaA – Key offerings
Exhibits157: Merck KGaA – Segment focus
Exhibits158: Novartis AG – Overview
Exhibits159: Novartis AG – Business segments
Exhibits160: Novartis AG – Key offerings
Exhibits161: Novartis AG – Segment focus
Exhibits162: Novo Nordisk AS – Overview
Exhibits163: Novo Nordisk AS – Business segments
Exhibits164: Novo Nordisk AS – Key offerings
Exhibits165: Novo Nordisk AS – Segment focus
Exhibits166: Pfizer Inc. – Overview
Exhibits167: Pfizer Inc. – Product / Service
Exhibits168: Pfizer Inc. – Key news
Exhibits169: Pfizer Inc. – Key offerings
Exhibits170: Protagonist Therapeutics Inc. – Overview
Exhibits171: Protagonist Therapeutics Inc. – Product / Service
Exhibits172: Protagonist Therapeutics Inc. – Key offerings
Exhibits173: Inclusions checklist
Exhibits174: Exclusions checklist
Exhibits175: Currency conversion rates for US$
Exhibits176: Research methodology
Exhibits177: Validation techniques employed for market sizing
Exhibits178: Information sources
Exhibits179: List of abbreviations



★調査レポート[肝硬変治療薬のグローバル市場2024-2028:経口剤、注射剤] (コード:IRTNTR76818-24)販売に関する免責事項を必ずご確認ください。
★調査レポート[肝硬変治療薬のグローバル市場2024-2028:経口剤、注射剤]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆